Citi downgrades Moderna to sell
In short
Citi analyst Geoff Meacham downgraded Moderna to sell, according to a market summary. The report says this came after Moderna had been rallying since mid-August, but it does not give the date of the call or the detailed reason.
The move could weigh on Moderna shares and biotech sentiment. The report does not state a price target or what event may have triggered the view.
What the reporting says
Citi analyst Geoff Meacham downgraded Moderna to sell, according to a publisher-supplied market summary. The report does not state when the downgrade was issued or give the analyst’s full rationale, only that the move followed a recent run-up in the stock. The immediate market implication is negative for Moderna, but the exact price target, timing and catalyst are not stated in the available reporting.
Why it matters
Citi analyst Geoff Meacham downgraded Moderna to sell in a publisher-supplied market summary. The note links the call to Moderna’s strong run since mid-August, but no exact date, target price, or detailed thesis is provided. The immediate effect is a negative read-through for Moderna shares and possibly broader biotech sentiment, though the source leaves the underlying catalyst unknown.